uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
QURE has more than doubled off its 52-week low of $7.76 on elevated volume (7.1× avg).
Summary
A securities fraud class action lawsuit has been filed against uniQure N.V. and certain executives, alleging they failed to disclose material information regarding the likelihood of accelerated FDA approval for its drug candidate, AMT-130. This lawsuit stems from the company's November 3, 2025, disclosure that the FDA no longer agreed that Phase I/II data for AMT-130 was adequate for a Biologics License Application (BLA) submission, which led to a significant 49% stock decline. The class action introduces a material legal and financial risk for uniQure, potentially resulting in substantial costs and management distraction. Investors have until April 13, 2026, to file lead plaintiff applications.
At the time of this announcement, QURE was trading at $16.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $7.76 to $71.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Acceswire.